Last reviewed · How we verify
Hyaluronic Acid and hydroxypropylmethylcellulose
Hyaluronic acid and hydroxypropylmethylcellulose form a viscoelastic lubricating and protective coating on the ocular surface.
Hyaluronic acid and hydroxypropylmethylcellulose form a viscoelastic lubricating and protective coating on the ocular surface. Used for Dry eye syndrome / keratoconjunctivitis sicca, Ocular surface protection and lubrication.
At a glance
| Generic name | Hyaluronic Acid and hydroxypropylmethylcellulose |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Hyaluronic acid is a natural humectant and lubricant that binds water and maintains corneal hydration, while hydroxypropylmethylcellulose (HPMC) is a viscous polymer that increases tear film stability and residence time. Together, these agents protect the corneal epithelium, reduce friction, and provide sustained lubrication for dry eye conditions.
Approved indications
- Dry eye syndrome / keratoconjunctivitis sicca
- Ocular surface protection and lubrication
Common side effects
- Transient blurred vision
- Eye irritation or discomfort
- Mild conjunctival hyperemia
Key clinical trials
- Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye (PHASE2)
- Protecting the Eyes of Gamers With Lubricating Eyedrops (NA)
- Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel (PHASE1)
- Medical vs Acupuncture for Dry Eye (NA)
- Evaluate The Improvement In Symptoms Of Patients Using Cationorm After Pterygium Surgery (PHASE4)
- Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye (NA)
- Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced (PHASE2)
- The Effect of Gland Expression on the Regeneration of Meibomian Gland (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: